Compare CLDI & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDI | PRSO |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 8.4M |
| IPO Year | N/A | 2001 |
| Metric | CLDI | PRSO |
|---|---|---|
| Price | $1.15 | $0.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 69.6K | ★ 311.8K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,001,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $35.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.15 |
| 52 Week Low | $1.10 | $0.52 |
| 52 Week High | $19.20 | $2.37 |
| Indicator | CLDI | PRSO |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 50.94 |
| Support Level | $1.12 | $0.91 |
| Resistance Level | $1.23 | $1.00 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 10.52 | 62.00 |
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.